We are live on ! Find out more
FTH

Faeth Therapeutics
FTH

20 hedge funds and large institutions have $760K invested in Faeth Therapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.09% less ownership

Funds ownership: 0.47% → 0.38% (-0.09%)

13% less funds holding

Funds holding: 23 → 20 (-3)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

34% less capital invested

Capital invested by funds: $1.16M → $760K (-$398K)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Holders
20
Holders Change
-3
Holders Change %
-13.04%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$20.2K
2
Renaissance Technologies
Renaissance Technologies
New York
+$9.75K
3
Barclays
Barclays
United Kingdom
+$1.22K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$865
5
Citigroup
Citigroup
New York
+$57

Top Sellers

Rank Fund Capital Flow
1
IC
Ikarian Capital
Texas
-$95.1K
2
XT
XTX Topco
Cayman Islands
-$30.8K
3
BFM
Boothbay Fund Management
New York
-$30.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$28.3K
5
BCM
Bridgeway Capital Management
Texas
-$23.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$231K -$4.22K -444 -1%
IC
2
Ikarian Capital
Texas
$177K -$95.1K -10,000 -31%
CCM
3
Catalio Capital Management
New York
$116K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$69.9K +$9.75K +1,025 +13%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$59.4K +$865 +91 +1%
BFM
6
Boothbay Fund Management
New York
$42.8K -$30.5K -3,207 -37%
UBS Group
7
UBS Group
Switzerland
$16.8K +$20.2K +2,127 New
Northern Trust
8
Northern Trust
Illinois
$10.2K – – –
State Street
9
State Street
Massachusetts
$10.2K – – –
CAM
10
Cresset Asset Management
Illinois
$7.75K – – –
NAS
11
NWF Advisory Services
California
$6.51K – – –
Raymond James Financial
12
Raymond James Financial
Florida
$5.52K – – –
Morgan Stanley
13
Morgan Stanley
New York
$3.63K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$2.13K -$19 -2 -0.7%
Barclays
15
Barclays
United Kingdom
$1.01K +$1.22K +128 New
JP Morgan Chase
16
JP Morgan Chase
New York
$276 – – –
BNP Paribas Financial Markets
17
BNP Paribas Financial Markets
France
$63 – – –
Bank of America
18
Bank of America
North Carolina
$56 – – –
Citigroup
19
Citigroup
New York
$49 +$57 +6 New
SS
20
SBI Securities
Japan
$36 +$10 +1 +25%
XT
21
XTX Topco
Cayman Islands
– -$30.8K -3,145 Closed
Citadel Advisors
22
Citadel Advisors
Florida
– -$28.3K -2,886 Closed
BCM
23
Bridgeway Capital Management
Texas
– -$23.5K -2,395 Closed
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
– -$18.6K -1,903 Closed
HF
25
HRT Financial
New York
– -$5K -580 Closed
1
2

FTH Hedge Fund Activity: Q1 2025 in Review

20 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Faeth Therapeutics (FTH) for Q1 2025, worth a combined $760K — down 34% from $1.16M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of FTH and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was UBS Group, opening a new position worth an estimated $20.2K. The largest seller was Ikarian Capital, cutting an estimated $95.1K.

  • 20 institutional investors held Faeth Therapeutics (FTH) as of Q1 2025, down from 23 in Q4 2024.
  • Funds reported $760K of Faeth Therapeutics stock for Q1 2025, down 34% quarter-over-quarter.
  • 3 funds opened new Faeth Therapeutics positions in Q1 2025 and 6 closed out, a net change of -3 holders.
  • The largest Faeth Therapeutics buyer in Q1 2025 was UBS Group, an estimated $20.2K added.
  • The largest Faeth Therapeutics seller in Q1 2025 was Ikarian Capital, an estimated $95.1K sold.

Based on aggregated 13F filings for Q1 2025.